[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641002":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":56,"centralContacts":60,"locations":43,"responsibleParty":66,"collaborators":43,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":70,"sex":76,"minAge":77,"maxAge":43,"enrollmentInfo":78,"targetDuration":43,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":112,"whyStopped":43,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":43},{"fullName":5,"class":6},"Therakos LLC","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Methoxsalen in Conjunction with Extracorporeal Photopheresis System (ECP)","EXPERIMENTAL","Participants will receive methoxsalen, in conjunction with ECP",[13,14],"Drug: methoxsalen","Device: Extracorporeal photopheresis (ECP)",{"label":16,"type":17,"description":18,"interventionNames":19},"Best Available Therapy (BAT)","ACTIVE_COMPARATOR","Participants with ir-colitis will receive either Infliximab or Vedolizumab as per the investigator's choice. Participants with ir-hepatitis will receive Mycophenolate Mofetil (MMF) or Azathioprine as per the investigator's choice.",[20,21,22,23],"Drug: Vedolizumab","Drug: Infliximab","Drug: Mycophenolate Mofetil (MMF)","Drug: Azathioprine",[25,32,39,44,48,52],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","methoxsalen","Sterile solution used in conjunction with CELLEX ECP",[9],[31],"UVADEX",{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"DEVICE","Extracorporeal photopheresis (ECP)","Methoxsalen is used in conjunction with the CELLEX ECP",[9],[38],"CELLEX",{"type":26,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"Vedolizumab","Vedolizumab will be administered intravenously",[16],null,{"type":26,"name":45,"description":46,"armGroupLabels":47,"otherNames":43},"Infliximab","Infliximab will be administered intravenously",[16],{"type":26,"name":49,"description":50,"armGroupLabels":51,"otherNames":43},"Mycophenolate Mofetil (MMF)","Mycophenolate Mofetil will be administered orally or intravenously",[16],{"type":26,"name":53,"description":54,"armGroupLabels":55,"otherNames":43},"Azathioprine","Azathioprine will be administered orally or intravenously",[16],[57],{"name":58,"affiliation":5,"role":59},"Isabelle T Seemann, Ph.D","STUDY_DIRECTOR",[61],{"name":62,"role":63,"phone":64,"phoneExt":43,"email":65},"Therakos TKS2001 Study Team","CONTACT","855-512-3327","Clinicaltrials@therakos.com",{"type":67,"investigatorFullName":43,"investigatorTitle":43,"investigatorAffiliation":43,"oldNameTitle":43,"oldOrganization":43},"SPONSOR","100641002","phase-2-phoenix-ecp--extracorporeal-photopheresis-for-immune-related-colitis-andor-hepatitis-in-advanced-melanoma-with-inadequate-response-to-steroid-exposure-100641002",false,"NCT07619898","PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and\u002For Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure","PHOENIX- A Phase 2, Randomized, Controlled, Open-label, Multicenter Study to Evaluate the Efficacy and Safety\u002FTolerability of Extracorporeal Photopheresis (ECP) Versus Best Available Therapy (BAT) for the Treatment of Immune-related Colitis or Hepatitis With Inadequate Response to Corticosteroids in Participants With Unresectable or Metastatic Melanoma Treated With Immune Checkpoint Inhibitors (ICI)","PHOENIX-ECP","Inclusion Criteria:\n\n1. Participants diagnosed with unresectable or metastatic melanoma ( Stage III and Stage IV) received ICI treatment (e.g., anti-PD-1, anti-PD-L1, anti-LAG-3, anti-CTLA-4 antibody, as ICI monotherapy or ICI combination therapy) and ICI paused or discontinued because of the development of ir-colitis or ir-hepatitis.\n2. Participants diagnosed with ir-colitis and\u002For ir-hepatitis with a severity of Grade 2 or higher, based on ASCO Guidelines (\n3. Participants with endoscopic evidence of ir-colitis\n4. Participants with inadequate response to corticosteroids, as defined per protocol\n5. Participants who have Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.\n\nExclusion Criteria:\n\n1. Presence of irAEs in addition to and other than ir-colitis and\u002For ir-hepatitis, with a higher severity grade than the irAE for inclusion (ir-colitis\u002Fir-hepatitis) based on ASCO guidelines.\n2. Participant has a diagnosis of uveal melanoma as the sole melanoma subtype\n3. Treatment of ir-colitis or ir-hepatitis with any systemic therapy other than corticosteroids\n4. Concurrent conditions which may require treatment with high dose corticosteroid (\\> 1 milligram per kilogram per day \\[mg\u002Fkg\u002Fday\\]) and interfere with the corticosteroid tapering schedule recommended by the protocol.\n5. Pre-existing liver disease\n6. Active alcohol use disorder\n7. Concomitant treatment with any chemotherapy or targeted therapy for the treatment of unresectable or metastatic melanoma.\n8. Use of any investigational agent within 5 half-lives of the investigational agent prior to randomization.\n9. Contraindications or known allergic reaction to any of study intervention and\u002For procedures\n10. Participants unable to tolerate the fluid shift associated with the ECP procedure.\n11. Positive result for active or previous viral infections: covid-19, hepatitis B\u002FC, CMV, EBV, adenovirus\n12. History of previous or concurrent malignancies within the last 3 years, other than unresectable or metastatic melanoma.","ALL","18 Years",{"count":79,"type":80},112,"ESTIMATED","INTERVENTIONAL",[83],"PHASE2","Extracorporeal photopheresis (ECP) is an immunomodulatory therapy in which the photoactivating agent methoxsalen (also known as UVADEX) is used in combination with ultraviolet A (UVA) light.\n\nImmune checkpoint inhibitor therapy is widely used for the treatment of several cancers, including melanoma. However, a common immune-related adverse event associated with this therapy is Immune-related colitis or hepatitis. Corticosteroids are typically the first-line treatment for this condition, but some participants do not respond adequately.\n\nThe purpose of this study is to evaluate the efficacy of ECP in the treatment of immune-related (ir)-colitis and ir-hepatitis with inadequate response to corticosteroids, and to compare its efficacy to other second-line immunosuppressant therapies. The ECP procedure in this study is performed using the CELLEX® device, a fully closed-loop extracorporeal blood circulation device. The CELLEX device is used in conjunction with methoxsalen.",[86,87,88],"Colitis","Hepatitis","Melanoma (Skin Cancer)",[90,91,92,93,94,95,96,97,98,99,100,31,101,102,103,104,105,106,107,108,86,109,110,111],"Melanoma","Immune-related adverse events","Immune-related colitis","Immune checkpoint inhibitor toxicity","Checkpoint inhibitor-induced colitis","Checkpoint inhibitor-induced hepatitis","Metastatic melanoma","Unresectable melanoma","Immune checkpoint Inhibitors","Extracorporeal photopheresis","ECP","Device","Methoxsalen","Steroid-refractory","Corticosteroid refractory","Phase 2 clinical trial","Randomized controlled trial","Cellex","8-Mop","Ir-AE","Ir-AE Colitis","Ir-AE Hepatitis","NOT_YET_RECRUITING","2026-05-27",{"date":115,"type":116},"2026-06-02","ACTUAL",{"date":118,"type":80},"2026-07",{"date":120,"type":80},"2029-12",{"name":5,"class":6}]